I have invested in dividends for 15 years—These dividend aristocrats built my passive income stream24/7 Wall Street • 06/03/25
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimen shows 95 percent progression-free survival at four years in transplant-eligible, newly diagnosed patients with multiple myeloma who achieved sustained MRD negativityPRNewsWire • 06/03/25
Early results from Johnson & Johnson's trispecific antibody show promising response in heavily pretreated multiple myeloma patientsPRNewsWire • 06/03/25
Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered lasting treatment-free remissions for at least five years in patients with relapsed or refractory multiple myelomaPRNewsWire • 06/03/25
Johnson & Johnson's AKEEGA® (niraparib and abiraterone acetate dual-action tablet) is the first PARP inhibitor combo to show improved efficacy in patients with HRR-mutated mHSPC vs. current standard of careGlobeNewsWire • 06/03/25
Johnson & Johnson leads with first PARP inhibitor combo to improve efficacy in patients with HRR-altered mCSPCPRNewsWire • 06/03/25
These 2 Dividend Stocks Have Grown Dividends For 50 Consecutive Years. Can That Streak Continue?24/7 Wall Street • 05/30/25
Johnson & Johnson (JNJ) Presents at the Bernstein's 41st Annual Strategic Decisions Conference (Transcript)Seeking Alpha • 05/28/25
Generating Passive Income: 3 Top Dow Dividend Stocks to Buy for 2025 and BeyondThe Motley Fool • 05/24/25
JNJ Down 6% in 3 Months: How to Play the Stock Amid Various ChallengesZacks Investment Research • 05/22/25
Johnson & Johnson to Participate in the Bernstein's 41st Annual Strategic Decisions ConferenceBusiness Wire • 05/21/25
U.S. FDA Oncologic Drugs Advisory Committee votes in favor of the benefit-risk profile of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for high-risk smoldering multiple myelomaPRNewsWire • 05/20/25